How to Get Dayvigo (Lemborexant) in Maine

Why Lemborexant Works Differently from Older Sleep Medications

Lemborexant belongs to the dual orexin receptor antagonist (DORA) class. Rather than broadly sedating the central nervous system the way benzodiazepines or Z-drugs do, it blocks orexin-A and orexin-B neuropeptides that promote wakefulness. The result is a medication that reduces the drive to stay awake without the respiratory depression risk associated with GABAergic agents [1].

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg both significantly improved objective sleep-onset latency compared to placebo at one month. The 10 mg dose reduced latency to persistent sleep by 10.5 minutes more than placebo (P<0.001), and improvements in wake-after-sleep-onset were sustained through the study period [1]. These findings led the FDA to approve Dayvigo in December 2019 for treating insomnia characterized by difficulty with sleep onset and/or sleep maintenance [2].

The orexin-blocking mechanism also produces a lower abuse potential relative to benzodiazepine receptor agonists. The FDA classified lemborexant as Schedule IV, the same category as zolpidem, but human abuse-potential studies showed lemborexant produced fewer "drug liking" effects than zolpidem at supratherapeutic doses [2]. That distinction matters for Maine prescribers evaluating patients with substance-use histories.

Telehealth Prescribing of Dayvigo in Maine

Maine law permits telehealth prescribing of Schedule IV controlled substances when a valid prescriber-patient relationship exists. You do not need an in-person visit first. A licensed physician, nurse practitioner, or physician assistant can evaluate you by synchronous video, establish a diagnosis of insomnia disorder, and transmit a Dayvigo prescription electronically to any Maine pharmacy.

The Maine Board of Licensure in Medicine requires that the prescriber hold an active Maine license or qualify under the state's interstate telehealth provisions. Prescribers using telehealth platforms must document a clinical evaluation equivalent in scope to an in-person encounter, including sleep history, medication reconciliation, and screening for contraindications such as narcolepsy (for which orexin antagonists are contraindicated) [2].

Several national telehealth platforms now serve Maine patients for insomnia. A typical workflow looks like this: complete an intake questionnaire, schedule a video visit (often available within 48 to 72 hours), receive a prescription sent to your chosen pharmacy, and pick up or have the medication shipped. Some platforms offer asynchronous follow-up messaging for dose adjustments.

The American Academy of Sleep Medicine endorsed telehealth for sleep disorder management in its 2020 position statement, noting that "telehealth can be used effectively for the diagnosis and management of a wide range of sleep disorders" [3]. For insomnia specifically, clinical outcomes via telehealth have been comparable to in-person care in multiple studies.

Who Can Prescribe Dayvigo in Maine: MD, NP, and PA Authority

Three prescriber types can write a Dayvigo prescription in Maine. Medical doctors (MDs and DOs) have unrestricted Schedule IV prescribing authority. Nurse practitioners with an active Maine APRN license prescribe independently. Maine removed collaborative-agreement requirements for NPs in 2023, meaning NPs do not need physician oversight to prescribe lemborexant.

Physician assistants in Maine prescribe Schedule IV drugs under their supervising physician's DEA registration unless they hold their own DEA number. PAs with independent DEA registrations can prescribe Dayvigo directly [4].

All three prescriber types must hold valid DEA registrations and Maine Controlled Substance Act registrations. Pharmacies will verify both before dispensing. If you are using a telehealth platform, confirm that the assigned provider is Maine-licensed and DEA-registered before your appointment.

MaineCare (Medicaid) Coverage and Prior Authorization

MaineCare covers Dayvigo, but it requires prior authorization (PA). The PA process exists because MaineCare's preferred drug list favors lower-cost insomnia medications first. Your prescriber will need to demonstrate that you meet specific criteria before MaineCare approves coverage.

Typical PA documentation requirements include: a confirmed diagnosis of insomnia disorder per DSM-5 or ICSD-3 criteria, documented failure of or contraindication to at least one first-line agent (usually a generic Z-drug like zolpidem or a sedating antidepressant like trazodone), and documentation that cognitive behavioral therapy for insomnia (CBT-I) was considered or attempted [5]. Some plans also require a statement that the patient does not have severe hepatic impairment, which is a labeled contraindication [2].

Processing time varies. Electronic PA submissions through CoverMyMeds or SureScripts typically receive a determination within 24 to 72 hours. Paper submissions may take five to seven business days. If denied, your prescriber can file a written appeal, and Maine requires insurers to provide an expedited review within 24 hours for urgent cases.

For commercially insured patients, coverage varies by plan. Eisai offers a manufacturer copay card that can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients, with a maximum annual benefit. The card does not apply to government insurance programs including MaineCare, Medicare Part D, or Tricare [6].

What Labs and Evaluations Are Needed Before Starting Dayvigo

No specific laboratory tests are required before prescribing lemborexant. The FDA prescribing information does not mandate baseline blood work [2]. This is different from some other sleep-adjacent medications. Prescribers do not need to order a sleep study (polysomnography) before initiating therapy, though they may request one if they suspect obstructive sleep apnea or another primary sleep disorder.

A thorough clinical evaluation should include screening for depression (insomnia is frequently comorbid with mood disorders), substance use history, concurrent medications metabolized by CYP3A (lemborexant is a CYP3A substrate, and strong CYP3A inhibitors are contraindicated), and a history of complex sleep behaviors such as sleepwalking [2].

Hepatic function deserves attention. Lemborexant exposure roughly doubles in patients with moderate hepatic impairment, and the recommended maximum dose drops to 5 mg. Severe hepatic impairment is a contraindication [2]. Prescribers treating patients with known liver disease should review recent liver function tests, though routine screening in healthy patients is not standard practice.

According to Endocrine Society guidelines on sleep and metabolic health, untreated insomnia contributes to insulin resistance and cardiometabolic risk [7]. Addressing sleep pharmacologically when behavioral interventions are insufficient or impractical carries benefits that extend beyond subjective sleep quality. This context often strengthens a prior authorization case for lemborexant.

Pharmacy Access in Maine: Retail and 503A Options

Maine has both retail chain pharmacies and independent pharmacies that stock or can order Dayvigo. CVS, Walgreens, Rite Aid, and Hannaford Pharmacy locations throughout the state can fill a Dayvigo prescription. Because lemborexant is a Schedule IV controlled substance, prescriptions must be transmitted electronically (Maine mandates EPCS for controlled substances) [8].

If a pharmacy does not have Dayvigo in stock, most can obtain it within one to two business days through their wholesale distributor. Rural Maine pharmacies with lower controlled-substance inventories may take slightly longer. Calling ahead to confirm availability saves a trip.

Mail-order pharmacy is another option. Express Scripts, CVS Caremark, and OptumRx all include Dayvigo on their formularies (subject to plan-specific PA requirements). Mail-order delivery to Maine addresses typically takes three to five business days after authorization clears.

503A compounding pharmacies licensed in Maine can compound lemborexant preparations if a patient-specific prescription exists. This might apply in cases where a patient needs a dose strength not commercially available or cannot swallow tablets. The Maine Board of Pharmacy oversees 503A compounding facilities and requires compliance with USP <795> standards. These pharmacies can ship compounded preparations directly to Maine patients [9].

Timeline: From First Visit to Medication in Hand

The full process from initial appointment to having Dayvigo in your medicine cabinet typically takes five to fourteen days. Here is a realistic breakdown.

Scheduling a telehealth visit takes one to three days depending on platform availability. The visit itself runs 15 to 30 minutes for a straightforward insomnia evaluation. If your prescriber sends the prescription electronically on the same day, a pharmacy without PA requirements can fill it within 24 hours.

PA adds time. Electronic PA submission and review takes one to three business days in most cases. Once approved, the pharmacy fills the prescription within hours. Total elapsed time with PA: five to ten days from visit to pickup.

For patients transferring an existing Dayvigo prescription from another state, Maine pharmacies can accept a transferred Schedule IV prescription from the originating pharmacy. The transferring pharmacist contacts the receiving Maine pharmacy directly. This process typically completes within one business day but requires that the original prescription still have valid refills remaining [10].

Dosing and Clinical Guidance for Lemborexant

The FDA-approved starting dose is 5 mg taken orally once per night, immediately before going to bed, with at least seven hours of planned sleep remaining. The dose can be increased to 10 mg if 5 mg is tolerated but insufficiently effective [2].

Taking lemborexant with or shortly after a heavy meal slows absorption and may delay sleep onset. The FDA label recommends against taking it with or immediately after a meal [2]. Patients should also avoid alcohol, which potentiates CNS depression.

The SUNRISE-2 trial (N=949) evaluated 12-month safety and found that lemborexant maintained efficacy without evidence of tolerance development over the full study period. Treatment-emergent adverse events were mostly mild; the most common were somnolence (10%), headache (6%), and dizziness (3%) [11]. Rebound insomnia after discontinuation was not observed at rates above placebo in clinical trials, which distinguishes lemborexant from some benzodiazepine receptor agonists.

Drug interactions require careful medication reconciliation. Coadministration with strong CYP3A inhibitors (itraconazole, clarithromycin, certain HIV protease inhibitors) is contraindicated. Moderate CYP3A inhibitors (fluconazole, erythromycin, diltiazem) require dose reduction to 5 mg maximum. Strong CYP3A inducers (rifampin, carbamazepine, phenytoin) may reduce lemborexant efficacy significantly [2].

How Lemborexant Compares to Other Insomnia Medications Available in Maine

Maine patients have access to several insomnia medication classes. Zolpidem (Ambien) and eszopiclone (Lunesta) are Z-drugs that act on GABA-A receptors. They work fast but carry risks of complex sleep behaviors, next-morning impairment, and dependence with long-term use. The FDA added boxed warnings to all three Z-drugs in 2019 [12].

Suvorexant (Belsomra) is the other FDA-approved DORA. It blocks the same orexin receptors but at different binding kinetics. Head-to-head, the SUNRISE-1 trial compared lemborexant directly against zolpidem extended-release and found that lemborexant 10 mg produced significantly better wake-after-sleep-onset reduction in the second half of the night compared to zolpidem ER 6.25 mg (P<0.01), while showing a cleaner next-morning residual-effect profile [1].

Trazodone, used off-label for insomnia at 25 to 100 mg, remains the most commonly prescribed sleep medication in the United States. It is generic, inexpensive, and does not require PA from most insurers. But it lacks strong randomized controlled trial data for insomnia, carries anticholinergic burden, and causes orthostatic hypotension, particularly in older adults [13].

For patients who have failed or cannot tolerate first-line agents, lemborexant offers a mechanistically distinct option with a favorable next-day functioning profile and no evidence of physical dependence in trials lasting up to 12 months.

Special Considerations for Older Adults in Maine

Maine has the oldest median age of any U.S. state (45.1 years per the 2024 Census estimate), which makes geriatric prescribing considerations especially relevant. Lemborexant does not require dose adjustment in elderly patients, and the SUNRISE-1 trial enrolled adults aged 55 and older specifically for its secondary analysis [1].

The American Geriatrics Society Beers Criteria list benzodiazepines and Z-drugs as potentially inappropriate for adults 65 and older due to fall risk, cognitive impairment, and delirium [14]. DORAs are not on the Beers list. This distinction gives prescribers treating older Maine residents a pharmacological rationale for choosing lemborexant over zolpidem or eszopiclone, and it strengthens PA appeals when an insurer's step-therapy protocol requires trying a Z-drug first.

Fall risk data from pooled SUNRISE analyses showed no statistically significant increase in falls with lemborexant compared to placebo in patients aged 55 and older [11]. That finding, combined with the absence of anticholinergic activity, positions lemborexant as a preferred pharmacological option for elderly insomnia when CBT-I alone is insufficient.